Sign in / Join Now
ETFs & Funds
Enanta Pharmaceuticals: A Potential Play On Drug-Resistant Bacteria $
Add a reply...
Latest StockTalks »
people get ENTA breaking news and analysis by email alert.
Get email alerts on ENTA »
Enanta Pharmaceuticals, Inc.
Get latest price
From other sites
Enanta Pharmaceuticals Announces AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
at TheStreet (Fri, 8:08AM)
Enanta Pharmaceuticals Presents Data On A Novel Non-Fusion Inhibitor Of Respiratory Syncytial Virus (RSV) At The 10th Annual Respiratory Syncytial Virus Conference
at TheStreet (Thu, 4:06PM)
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-alcoholic Steatohepatitis (NASH)
at TheStreet (Wed, 4:12PM)
Commit To Buy Enanta Pharmaceuticals At $20, Earn 11.5% Annualized Using Options
at TheStreet (Tue, 11:38AM)
Enanta Pharmaceuticals Announces Data On Eight-Week Treatment Of AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) + EXVIERA® (dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C
at TheStreet (Sep 23, 2016)